恩格列净保护心肌及调控线粒体功能的机制研究  

Research on Mechanisms of Protection of Empagliflozin on Myocardium and Regulation of Mitochondrial Function

作　　者：李永光[1] 徐伟泽 魏钧伯[1] 沈成兴 LI Yongguang;XU Weize;WEI Junbo;SHEN Chengxing(Department of Cardiology,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Shanghai 200233,China;Department of Clinical Medicine,Chengde Medical University,Chengde 067000,China)

机构地区：[1]上海交通大学附属第六人民医院心内科,上海200233 [2]承德医学院临床医学系,河北承德067000

出　　处：《医学综述》2022年第8期1463-1467,共5页Medical Recapitulate

基　　金：国家自然科学基金(81800331);上海市卫生健康委员会科研课题(201940079)。

摘　　要：恩格列净作为一种新型降糖药物,是钠-葡萄糖协同转运蛋白(SGLT)2抑制剂的一种,最初作用于肾脏。SGLT2抑制剂同时也参与心血管方面的保护,对心功能、血压甚至代谢等均有调控作用。但心肌中并不存在SGLT2受体,因此恩格列净的心肌获益并不仅依靠对SGLT2的抑制作用,还有其他机制参与其中。线粒体作为细胞的重要组成部分,在氧化应激、炎症反应及能量代谢方面均具有重要作用,而恩格列净可参与线粒体呼吸链、离子通道以及相应信号通路的调控。因此,深入研究恩格列净调控线粒体功能以及在心肌中的作用机制尤为必要。As a new hypoglycemic drug,empagliflozin is one of the inhibitors of sodium-dependent glucose cotransporter(SGLT)2,which was initially discovered acting in kidney.SGLT2 inhibitors participate in cardiovascular protection and regulate cardiac function,blood pressure and even metabolism.But there is no SGLT2 receptor in the heart.Therefore,the myocardial benefit of empagliflozin does not only depend on the inhibition of SGLT2,but also involves other mechanisms.As an important part of the cells,mitochondria plays an important role in oxidative stress,inflammatory response and energy metabolism,and empagliflozin is involved in the regulation of mitochondrial respiratory chain,ion channels and the corresponding signal pathways.It is particularly necessary to discover the mechanism of empagliflozin in the regulation of mitochondrial function and effect in the myocardium.

关 键 词：恩格列净 钠-葡萄糖协同转运蛋白2抑制剂 线粒体 

分 类 号：R341[医药卫生—基础医学]